Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882553 | 0.90 | EPHB4 (0.52) | EPHB4KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL10330903 | 0.90 | EPHB4 (0.43) | EPHB4KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL5592906 | 0.84 | KMT2A (0.50) | EPHB4KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL5601157 | 0.81 | THRB (0.49) | EPHB4KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL5592585 | 0.81 | MEN1 (0.47) | EPHB4KMT2AMEN1POLBIGF1R | |
| SCHEMBL5959896 | 0.81 | MEN1 (0.46) | EPHB4KMT2AMEN1POLBIGF1R | |
| SCHEMBL5959796 | 0.80 | MEN1 (0.50) | EPHB4KMT2AMEN1POLBIGF1R | |
| SCHEMBL5585966 | 0.79 | MEN1 (0.48) | EPHB4KMT2AMEN1POLBIGF1R | |
| SCHEMBL5592688 | 0.79 | ERBB4 (0.55) | EPHB4KMT2AMEN1POLBALDH1A1 | |
| SCHEMBL5600309 | 0.79 | CHEK1 (0.51) | EPHB4KMT2AMEN1POLBIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007024294-A2 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20060270702-A1 | Certain substituted ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-11-30 | — | — | US | claimed |
| US-8222421-B2 | Certain substituted ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222421-B2 | Certain substituted ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222421-B2 | Certain substituted ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20100286190-A1 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286190-A1 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286190-A1 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. | 2010-11-11 | — | — | US | disclosed |
| US-7777040-B2 | Certain substituted ureas, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777040-B2 | Certain substituted ureas, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777040-B2 | Certain substituted ureas, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2007024294-A2 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024294-A2 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060270702-A1 | Certain substituted ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270702-A1 | Certain substituted ureas, as modulators of kinase activity | UCK2, CHUK, TK1 | EPHB4 2792/4885KMT2A 3039/4885MEN1 3522/4885 |
| US-20100286190-A1 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | UCK2, CHUK, TK1 | EPHB4 2792/4885KMT2A 3039/4885MEN1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.